Author: Tang, Mei San; Case, James Brett; Franks, Caroline E; Chen, Rita E; Anderson, Neil W; Henderson, Jeffrey P; Diamond, Michael S; Gronowski, Ann M; Farnsworth, Christopher W
Title: Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays Cord-id: nugk4d55 Document date: 2020_9_7
ID: nugk4d55
Snippet: INTRODUCTION: Commercially available SARS-CoV-2 serological assays based on different viral antigens have been approved for the qualitative determination of anti-SARS-CoV-2 antibodies. However, there are limited published data associating the results from commercial assays with neutralizing antibodies. METHODS: 67 specimens from 48 patients with PCR-confirmed COVID-19 and a positive result by the Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, or EUROIMMUN SARS-CoV-2 IgG assays and 5 contr
Document: INTRODUCTION: Commercially available SARS-CoV-2 serological assays based on different viral antigens have been approved for the qualitative determination of anti-SARS-CoV-2 antibodies. However, there are limited published data associating the results from commercial assays with neutralizing antibodies. METHODS: 67 specimens from 48 patients with PCR-confirmed COVID-19 and a positive result by the Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, or EUROIMMUN SARS-CoV-2 IgG assays and 5 control specimens were analyzed for the presence of neutralizing antibodies to SARS-CoV-2. Correlation, concordance, positive percent agreement (PPA), and negative percent agreement (NPA) were calculated at several cutoffs. Results were compared in patients categorized by clinical outcomes. RESULTS: The correlation between SARS-CoV-2 neutralizing titer (EC(50)) and the Roche, Abbott, and EUROIMMUN assays was 0.29, 0.47, and 0.46 respectively. At an EC(50) of 1:32, the concordance kappa with Roche was 0.49 (95% CI; 0.23-0.75), with Abbott was 0.52 (0.28-0.77), and with EUROIMMUN was 0.61 (0.4-0.82). At the same neutralizing titer, the PPA and NPA for the Roche was 100% (94-100) & 56% (30-80); Abbott was 96% (88-99) & 69% (44-86); and EUROIMMUN was 91% (80-96) & 81% (57-93) for distinguishing neutralizing antibodies. Patients who were intubated, had cardiac injury, or acute kidney injury from COVID-19 infection had higher neutralizing titers relative to those with mild symptoms. CONCLUSION: COVID-19 patients generate an antibody response to multiple viral proteins such that the calibrator ratios on the Roche, Abbott, and EUROIMMUN assays are all associated with SARS-CoV-2 neutralization. Nevertheless, commercial serological assays have poor NPA for SARS-CoV-2 neutralization, making them imperfect proxies for neutralization.
Search related documents:
Co phrase search for related documents- abbott assay and low sensitivity: 1, 2, 3
- abbott diagnostics and low sensitivity: 1, 2
- abbott roche and low medium: 1
- abbott roche and low sensitivity: 1, 2
- abbott sars and low concordance: 1, 2
- abbott sars and low medium: 1
- abbott sars and low sensitivity: 1, 2, 3, 4
- abbott sars igg assay and low sensitivity: 1
- accurately determine and low sensitivity: 1
- acute aki kidney injury and low medium: 1
Co phrase search for related documents, hyperlinks ordered by date